Daniel Lenihan Archives
Heart failure “dashboard”
Jan. 5, 2017—A new computer algorithm developed at Vanderbilt could save billions of dollars in health care costs by identifying patients at risk for readmission after being hospitalized for heart failure.
Prostate cancer survivors’ risk of heart disease studied
Feb. 4, 2016—The 3 million prostate cancer survivors in the United States are likely to die from something other than cancer, thanks to early detection, effective treatment and the disease’s slow progression.
VUMC set to host inaugural Global Cardio-Oncology Summit
Oct. 15, 2015—Vanderbilt University Medical Center is hosting the first Global Cardio-Oncology Summit on Oct. 15-16, at the Hilton Nashville. The summit models a leading edge, interdisciplinary approach to cardio-oncology.
Study to explore myeloma treatment’s impact on heart
Feb. 5, 2015—Vanderbilt is embarking on an observational study to define and understand how a promising treatment for multiple myeloma affects the heart.
Program focuses on heart health of cancer patients
Oct. 2, 2014—The Vanderbilt Cardio-Oncology program has fostered a special collaborative relationship combining the expertise of cardiologists and oncologists to understand the effects of cancer therapy on the heart. This type of collaboration is now helping to define the cardiovascular health of more than 14 million cancer survivors in the United States.
Heart failure therapy shows promise in early clinical trial
Mar. 14, 2013—Vanderbilt University Medical Center and Acorda Therapeutics Inc. released findings from a Phase 1 clinical trial of glial growth factor 2 (GGF2) last week at the American College of Cardiology Annual Scientific Session in San Francisco.
Trial tests novel treatment for heart failure patients
May. 27, 2011—A new implantable device currently being studied gives heart failure patients the ability to monitor their heart and take action when their condition begins to worsen.
